Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta‐analysis
Javed, Asma , Jumean, Marwan , Murad, M. Hassan , Okorodudu, Daniel, Kumar, Seema , Sochor, Ondřej , Lopez‐Jimenez, Francisco, Somers, Virend K. , López-Jiménez, Francisco , Murad, M Hassan

Pediatric Obesity | June 25, 2014 | Volume: 10 | Issue: 3 | Pages: 234-244

10.1111/ijpo.242 | PMID 24961794 Get It

SummaryBackgroundThe ideal means of identifying obesity in children and adolescents has not been determined although body mass index (BMI) is the most widely used screening tool.ObjectiveWe performed a systematic review and meta‐analysis of studies assessing the diagnostic performance of BMI to detect adiposity in children up to 18 years.MethodsData sources were EMBASE, MEDLINE, Cochrane, Database of Systematic Reviews Cochrane CENTRAL, Web of Science and SCOPUS up to March 2013. Studies providing measures of diagnostic performance of BMI and using body composition technique for body fat percentage measurement were included.ResultsThirty‐seven eligible studies that evaluated 53 521 patients, with mean age ranging from 4 to 18 years were included in the meta‐analysis. Commonly used BMI cut‐offs for obesity showed pooled sensitivity to detect high adiposity of 0.73 (confidence interval [CI] 0.67–0.79), specificity of 0.93 (CI 0.88–0.96) and diagnostic odds ratio of 36.93 (CI 20.75–65.71). Males had lower sensitivity. Moderate heterogeneity was observed (I2 = 48%) explained in meta‐regression by differences across studies in race, BMI cut‐off, BMI reference criteria (Center for Disease Control vs. International Obesity Task Force) and reference standard method assessing adiposity.ConclusionBMI has high specificity but low sensitivity to detect excess adiposity and fails to identify over a quarter of children with excess body fat percentage.
Allergic Diseases and Risk of Hematopoietic Malignancies in a Cohort of Postmenopausal Women: A Report from the Iowa Women's Health Study
Linabery, Amy M. , Prizment, Anna E. , Anderson, Kristin E. , Cerhan, James R. , Poynter, Jenny N. , Ross, Julie A. , Cerhan, James R , Prizment, Anna E

Cancer Epidemiology, Biomarkers & Prevention | June 25, 2014 | Volume: 23 | Issue: 9 | Pages: 1903-1912

10.1158/1055-9965.epi-14-0423 | PMID 24962839 Get It

Abstract Background: Allergic diseases signify immune dysregulation attributable to underlying genetics and environmental exposures. Associations between various allergies and hematopoietic cancers have been observed, albeit inconsistently; however, few prospective studies have examined the risk, and even fewer among older adults. Methods: We examined risk of incident hematopoietic cancers in those reporting allergic diseases in a population-based cohort of 22,601 older women (Iowa Women's Health Study). Self-reported allergic status, including asthma, hay fever, eczema, and/or other allergies, was determined via questionnaire in 1997 (mean age, 72 years; range, 63–81 years). Incident cancers were ascertained by linkage with the Iowa Cancer Registry from 1997 to 2011. Cox proportional hazards regression was performed to estimate multivariate-adjusted HR and 95% confidence intervals (CI) for myeloid (N = 177) and lymphoid (N = 437) malignancies, respectively. Results: Allergic diseases were not associated with risk of myeloid (HR, 1.00; 95% CI, 0.72–1.37) or lymphoid (HR, 0.99; 95% CI, 0.81–1.22) malignancies overall, or for most allergic and malignant subtypes examined. Self-reported asthma was positively associated with development of myelodysplastic syndrome (MDS; HR, 2.00; 95% CI, 0.93–4.32). In addition, there was a 30% to 40% decrease in risk of both lymphoid and myeloid cancers in those reporting rural residences but no association in those reporting urban residences; the interaction between residence and allergy was statistically significant for lymphoid malignancies (Pinteraction = 0.05). Conclusions and Impact: These results suggest that asthma may contribute to the pathogenesis of MDS, a finding consistent with the chronic antigen stimulation hypothesis. Susceptibility differences by location of residence are concordant with the hygiene hypothesis and merit additional exploration. Cancer Epidemiol Biomarkers Prev; 23(9); 1903–12. ©2014 AACR.
Characterization of SEMA3A -Encoded Semaphorin as a Naturally Occurring K v 4.3 Protein Inhibitor and its Contribution to Brugada Syndrome
Boczek, Nicole J. , Ye, Dan , Johnson, Eric K. , Wang, Wei , Crotti, Lia , Tester, David J. , Dagradi, Federica , Mizusawa, Yuka , Torchio, Margherita , Alders, Mariëlle , Giudicessi, John R. , Wilde, Arthur A.M. , Schwartz, Peter J. , Nerbonne, Jeanne M. , Ackerman, Michael J. , Crotti, Lia , Schwartz, Peter J. , Dagradi, Federica

Circulation Research | June 25, 2014 | Volume: 115 | Issue: 4 | Pages: 460-469

10.1161/circresaha.115.303657 | PMID 24963029 Get It

Rationale : Semaphorin 3A ( SEMA3A )-encoded semaphorin is a chemorepellent that disrupts neural patterning in the nervous and cardiac systems. In addition, SEMA3A has an amino acid motif that is analogous to hanatoxin, an inhibitor of voltage-gated K + channels. SEMA3A -knockout mice exhibit an abnormal ECG pattern and are prone to ventricular arrhythmias and sudden cardiac death. Objective : Our aim was to determine whether SEMA3A is a naturally occurring protein inhibitor of K v 4.3 (I to ) channels and its potential contribution to Brugada syndrome. Methods and Results : K v 4.3, Na v 1.5, Ca v 1.2, or K v 4.2 were coexpressed or perfused with SEMA3A in HEK293 cells, and electrophysiological properties were examined via whole-cell patch clamp technique. SEMA3A selectively altered K v 4.3 by significantly reducing peak current density without perturbing K v 4.3 cell surface protein expression. SEMA3A also reduced I to current density in cardiomyocytes derived from human-induced pluripotent stem cells. Disruption of a putative toxin binding domain on K v 4.3 was used to assess physical interactions between SEMA3A and K v 4.3. These findings in combination with coimmunoprecipitations of SEMA3A and K v 4.3 revealed a potential direct binding interaction between these proteins. Comprehensive mutational analysis of SEMA3A was performed on 198 unrelated SCN5A genotype–negative patients with Brugada syndrome, and 2 rare SEMA3A missense mutations were identified. The SEMA3A mutations disrupted SEMA3A’s ability to inhibit K v 4.3 channels, resulting in a significant gain of K v 4.3 current compared with wild-type SEMA3A. Conclusions : This study is the first to demonstrate SEMA3A as a naturally occurring protein that selectively inhibits K v 4.3 and SEMA3A as a possible Brugada syndrome susceptibility gene through a K v 4.3 gain-of-function mechanism.
Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4
Roemeling, Christina A. Von , Marlow, Laura A. , Grebe, Stefan K., Anastasiadis, Panagiotis Z., Copland, John A. , von Roemeling, Christina A, Radisky, Derek C. , Cooper, Simon J, Tun, Han W. , Cooper, Simon JR , von Roemeling, Christina A , Marlow, Laura

Cancer Research | June 24, 2014 | Volume: 74 | Issue: 17 | Pages: 4796-4810

10.1158/0008-5472.can-14-0210 | PMID 24962026 Get It

Abstract Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease. Cancer Res; 74(17); 4796–810. ©2014 AACR.
Re‐defining the unique roles for eosinophils in allergic respiratory inflammation
Jacobsen, Elizabeth A. , Lee, N. A., Lee, J. J., Lee, N.A., Jacobsen, Elizabeth A

Clinical & Experimental Allergy | June 24, 2014 | Volume: 44 | Issue: 9 | Pages: 1119-1136

10.1111/cea.12358 | PMID 24961290 Get It

SummaryThe role of eosinophils in the progression and resolution of allergic respiratory inflammation is poorly defined despite the commonality of their presence and in some cases their use as a biomarker for disease severity and/or symptom control. However, this ambiguity belies the wealth of insights that have recently been gained through the use of eosinophil‐deficient/attenuated strains of mice that have demonstrated novel immunoregulatory and remodelling/repair functions for these cells in the lung following allergen provocation. Specifically, studies of eosinophil‐deficient mice suggest that eosinophils contribute to events occurring in the lungs following allergen provocation at several key moments: (i) the initiating phase of events leading to Th2‐polarized pulmonary inflammation, (ii) the suppression Th1/Th17 pathways in lung‐draining lymph nodes, (iii) the recruitment of effector Th2 T cells to the lung, and finally, (iv) mechanisms of inflammatory resolution that re‐establish pulmonary homoeostasis. These suggested functions have recently been confirmed and expanded upon using allergen provocation of an inducible eosinophil‐deficient strain of mice (iPHIL) that demonstrated an eosinophil‐dependent mechanism(s) leading to Th2 dominated immune responses in the presence of eosinophils in contrast to neutrophilic as well as mixed Th1/Th17/Th2 variant phenotypes in the absence of eosinophils. These findings highlighted that eosinophils are not exclusively downstream mediators controlled by T cells, dendritic cells (DC) and/or innate lymphocytic cells (ILC2). Instead, eosinophils appear to be more aptly described as significant contributors in complex interrelated pathways that lead to pulmonary inflammation and subsequently promote resolution and the re‐establishment of homoeostatic baseline. In this review, we summarize and put into the context the evolving hypotheses that are now expanding our understanding of the roles eosinophils likely have in the lung following allergen provocation.
Histopathological findings in cutaneous small-vessel vasculitis associated with solid-organ malignancy
Podjasek, Joshua O., Wetter, David A. , Wieland, Carilyn N. , Camilleri, Michael , Lohse, Christine M.

British Journal of Dermatology | June 24, 2014 | Volume: 171 | Issue: 6 | Pages: 1397-1401

10.1111/bjd.13202 | PMID 24958433 Get It

Faculty Opinions recommendation of Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension.
Martin, Yvette N. , Prakash, Y. S.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 24, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718340237.793496478 Get It

Novel therapeutic agents in neurogastroenterology: advances in the past year
Camilleri, Michael

Neurogastroenterology & Motility | June 24, 2014 | Volume: 26 | Issue: 8 | Pages: 1070-1078

10.1111/nmo.12386 | PMID 24953086 Get It

Abstract Background There have been significant advances in understanding the pathophysiological mechanisms in patients with neurogastroenterological disorders including irritable bowel syndrome (IBS) and functional abdominal pain, functional diarrhea, chronic constipation, gastroparesis, and functional dyspepsia. These advances have led to the development of novel pharmacological therapy of neurogastroenterological disorders. Purpose To review peer‐reviewed articles or prominent preliminary communications presented in the past year regarding medications in development for functional gastrointestinal disorders or gastroparesis. The medications fall into two main categories: first, established classes of medications within established classes, such as 5‐HT3 receptor antagonists and 5‐HT4 receptor agonists, and second, new classes of medications such as a combined μ‐opioid agonist and δ‐antagonist, or a small molecule ghrelin agonist.
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Rajkumar, S. Vincent , Dispenzieri, Angela , Lacy, Martha Q. , Kapoor, Prashant , Dingli, David , Lust, John A., Zeldenrust, Steven R., Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Rajkumar, S Vincent , Gonsalves, Wilson I. , Go, Ronald S. , Gupta, Vinay Kumar , Singh, Preet Paul , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Dingli, David

Blood | June 24, 2014 | Volume: 124 | Issue: 6 | Pages: 907-912

10.1182/blood-2014-03-565051 | PMID 24957143 Get It

Key Points Survival of patients with primary plasma cell leukemia has improved in recent years, but is still inferior to those patients with multiple myeloma. This survival benefit appears to be mainly in patients older than 65 years of age.